Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Modulation sAPP, sAAP α and BDNF levels in individuals diagnosed with FXS and ASD

Modulation sAPP, sAAP α and BDNF levels in individuals diagnosed with FXS and ASD

US Patent 9770423 · Granted Sep 26, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and AS2023
Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and AS2023
Methods of reducing neuroinflammation or toxicity induced by amyloid beta (abeta2022
Compositions and methods for treatment of fragile X syndrome2022
Peptides and methods for treatment of neurodegenerative diseases2020
Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and AS2020
Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and AS2020
Compositions and methods for treatment of fragile X syndrome2020
Compositions and methods for treatment of Fragile X Syndrome2018
Material and methods for treating developmental disorders including comorbid and2018
Compositions and methods for treatment of fragile X syndrome2017
Compositions and methods for treating an autism spectrum disorder2017